ENDP - Endo Non-GAAP EPS of -$0.03 beats by $0.11 revenue of $569.11M beats by $44.54M
- Endo press release ( NASDAQ: ENDP ): Q2 Non-GAAP EPS of -$0.03 beats by $0.11 .
- Revenue of $569.11M (-20.3% Y/Y) beats by $44.54M .
- As of June 30, 2022, the Company had approximately $1.2 billion in unrestricted cash; $8.1 billion of debt; and a net debt to adjusted EBITDA ratio of 5.6. These amounts reflect the Company's payment of $35 million to acquire 6 sterile injectable product candidates and a $30 million upfront payment related to a Phase 3 injectable compound for the treatment of osteoarthritis knee pain.
- Shares -23% PM
For further details see:
Endo Non-GAAP EPS of -$0.03 beats by $0.11, revenue of $569.11M beats by $44.54M